Protocol Ledger

NCT05926960 · Phase II · TERMINATED

A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma

Interventional Phase II clinical trial protocol NCT05926960 sponsored by Pfizer in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-06-13 Enrollment: 38 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05926960
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)38 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05926960
Protocol FieldVerified Registry Value
NCT IdentifierNCT05926960
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment38 participants (ACTUAL)
Registered Start Date2023-06-13
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05926960
Hospital Research SiteLocationSite Profile
Universitaetsklinikum TuebingenTübingen, GermanyOpen Hospital Dossier ->
Medizinische Hochschule HannoverHanover, GermanyOpen Hospital Dossier ->
Universitaetsklinikum EssenEssen, GermanyOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI